




11477

**Schematic**




**Table of features**

Element	Description	Position
<b>5' cap</b>	A specific capping structure at the 5'-end for improved RNA stability and translational efficiency.	1-2
<b>5'-UTR (hAg-Kozak)</b>	5'-UTR sequence derived from the human alpha-globin RNA with an optimized "Kozak sequence".	3-53
<b>sec</b>	The secretory signal peptide "sec" derived from the sequence encoding the human MHC Class I complex alpha chain "HLA-I, Cw*" is used as a fusion-protein tag to improve antigen processing and presentation.	54-131
<b>GS</b>	Sequences that code for short GS-rich linker peptides generally consisting of the amino acids glycine and serine (usually GGSGGGGSGG).	132-161, 702-731 and 927-968
<b>NY-ESO-1</b>	Codon-optimized sequences encoding the target protein NY-ESO-1	162-701
<b>P2P16</b>	Sequence coding for tetanus toxoid-derived helper epitopes to break immunological tolerance.	732-926
<b>MITD</b>	MITD corresponds to the transmembrane and cytoplasmic domain of the MHC class I molecule and is used as a fusion-protein tag to improve antigen processing and presentation.	969-1139
<b>3'-UTR (FI element)</b>	The 3'-UTR is a combination of two sequence elements derived from the AES mRNA (called F) and the mitochondrial encoded 12S ribosomal RNA (called I) to confer RNA stability and highest total protein expression.	1140-1456
<b>Poly(A)</b>	A poly(A)-tail measuring 110 nucleotides in length, consisting of a stretch of 30 adenosine residues, followed by a 10-nucleotide linker sequence and another 70 adenosine residues.	1457-1566



Abbreviations: AES = amino terminal enhancer of split; GS = glycine and serine; HLA = human leukocyte antigen, MHC = major histocompatibility complex; MITD = MHC class I transmembrane domain; UTR = untranslated region.

**5'- capping structure = G<sup>1</sup>G<sup>2</sup>: m<sup>7</sup>Guo+2'OMe-5'-p-(R)p<sup>S</sup>-p-5'-G**



**1-2** : cap m<sup>7</sup>Guo+2'OMe-5'-p-(R)p<sup>S</sup>-p-5'-G; **3-53** : 5'UTR; **54-131** : sec; **132-161** : G<sub>2</sub>SG<sub>4</sub>SG<sub>2</sub> linker; **162-701** : NY-ESO1 antigen; **702-731** : G<sub>2</sub>SG<sub>4</sub>SG<sub>2</sub> linker; **732-926** : P2P16 tetanus toxoid-derived helper epitopes; **927-968** : GS<sub>2</sub>G<sub>4</sub>SPG<sub>3</sub>S<sub>2</sub> linker; **969-1139** : MITD; **1140-1456** : FI element (3' UTR); **1457-1566** : A30L70 polyA tail.

**Sequence / Séquence / Secuencia**

<b>GGGGCGAACU</b>	<b>AGUAUUCUUC</b>	<b>UGGUCCCCAC</b>	<b>AGACUCAGAG</b>	<b>AGAACCCGCC</b>	50
<b>ACCAUGAGAG</b>	<b>UGAUGGCCCC</b>	<b>CAGAACCUG</b>	<b>AUCCUGCUGC</b>	<b>UGUCUGGCGC</b>	100
<b>CCUGGCCUG</b>	<b>ACAGAGACAU</b>	<b>GGGCCGGAAG</b>	<b>CGGCGGCUCU</b>	<b>GGAGGAGGCG</b>	150
<b>GCUCCGGAGG</b>	<b>CAUGCAGGCC</b>	<b>GAGGGCAGAG</b>	<b>GAACAGGCGG</b>	<b>CAGCACAGGC</b>	200
<b>GACGCAGAUG</b>	<b>GACCAGGCGG</b>	<b>CCCUGGAAUC</b>	<b>CCUGAUGGCC</b>	<b>CAGGCGGCAA</b>	250
<b>UGCUGGGGGA</b>	<b>CCAGGAGAAG</b>	<b>CUGGCGCCAC</b>	<b>AGGCGGGAGA</b>	<b>GGACCUAGAG</b>	300
<b>GAGCUGGAGC</b>	<b>CGCUAGAGCU</b>	<b>UCUGGACCUG</b>	<b>GGGGAGGCGC</b>	<b>CCCUAGAGGA</b>	350
<b>CCACAUGGAG</b>	<b>GCGCUGCCAG</b>	<b>CGGCCUGAAU</b>	<b>GGCUGCUGCA</b>	<b>GAUGC GGCGC</b>	400
<b>CAGAGGCCCU</b>	<b>GAGAGCCGGC</b>	<b>UGCUGGAAUU</b>	<b>CUACCUGGCC</b>	<b>AUGCCCUUCG</b>	450
<b>CCACCCCAU</b>	<b>GGAAGCCGAG</b>	<b>CUGGCCAGAA</b>	<b>GAUCCUGGC</b>	<b>UCAGGACGCU</b>	500
<b>CCUCCUCUGC</b>	<b>CUGUGCCCGG</b>	<b>CGUGCUGCUG</b>	<b>AAAGAAUUCA</b>	<b>CCGUGUCCGG</b>	550
<b>CAACAUCUGC</b>	<b>ACCAUCAGAC</b>	<b>UGACAGCCGC</b>	<b>CGAUCACAGA</b>	<b>CAGCUCCAGC</b>	600
<b>UGAGCAUCAG</b>	<b>CUCUUGCCUG</b>	<b>CAGCAGCUGA</b>	<b>GCCUGCUGAU</b>	<b>GUGGAUCACC</b>	650
<b>CAGUGCUIUC</b>	<b>UGCCCUGUUU</b>	<b>CCUGGCCAG</b>	<b>CCACCCAGCG</b>	<b>GACAGAGAAG</b>	700
<b>CGGAGGAUCC</b>	<b>GGUGGUGGCG</b>	<b>GCAGCGGCGG</b>	<b>CAAGAAGCAG</b>	<b>UACAUCAAGG</b>	750
<b>CCAACAGCAA</b>	<b>GUUCAUCGGC</b>	<b>AUCACCGAGC</b>	<b>UGAAGAAGCU</b>	<b>GGGAGGGGGC</b>	800
<b>AAACGGGGAG</b>	<b>GCGGCAAAAA</b>	<b>GAUGACCAAC</b>	<b>AGCGUGGACG</b>	<b>ACGCCUGAU</b>	850
<b>CAACAGCACC</b>	<b>AAGAUCUACA</b>	<b>GCUACUCCC</b>	<b>CAGCGUGAUC</b>	<b>AGCAAAGUGA</b>	900
<b>ACCAGGGCGC</b>	<b>UCAGGGCAAG</b>	<b>AAACUGGGCU</b>	<b>CUAGCGGAGG</b>	<b>GGGAGGCUCU</b>	950
<b>CCUGGCCGGG</b>	<b>GAUCUAGCAU</b>	<b>CGUGGGAAUU</b>	<b>GUGGCAGGAC</b>	<b>UGGCAGUGCU</b>	1000
<b>GGCCGUGGUG</b>	<b>GUGAUCGGAG</b>	<b>CCGUGGUGGC</b>	<b>UACCGUGAUG</b>	<b>UGCAGACGGA</b>	1050
<b>AGUCCAGCGG</b>	<b>AGGCAAGGGC</b>	<b>GGCAGCUACA</b>	<b>GCCAGGCCGC</b>	<b>CAGCUCUGAU</b>	1100
<b>AGCGCCAGG</b>	<b>GCAGCGACGU</b>	<b>GUCACUGACA</b>	<b>GCCUAGU AAC</b>	<b>UCGAGCUGGU</b>	1150
<b>ACUGCAUGCA</b>	<b>CGCAAUGCUA</b>	<b>GCUGCCCCUU</b>	<b>UCCCUGUCCUG</b>	<b>GGUACCCCGA</b>	1200
<b>GUCUCCCCCG</b>	<b>ACCUCGGGUC</b>	<b>CCAGGUAUGC</b>	<b>UCCCACCUCC</b>	<b>ACCUGCCCCA</b>	1250
<b>CUCACCACCU</b>	<b>CUGCUAGUUC</b>	<b>CAGACACCUC</b>	<b>CCAAGCACGC</b>	<b>AGCAAUGCAG</b>	1300
<b>CUCAAACGC</b>	<b>UUAGCCUAGC</b>	<b>CACACCCCA</b>	<b>CGGGAAACAG</b>	<b>CAGUGAUUAA</b>	1350



**WHO**  
**International Nonproprietary Names Programme**

7/2020

*CCUUUAGCAA UAAACGAAAG UUUUACUAAG CUAUACUAAC CCCAGGGUUG 1400*  
*GUCAAUUUCG UGCCAGCCAC ACCGAGACCU GGUCCAGAGU CGCUAGCCGC 1450*  
*GUCGCUAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAGCAU AUGACUAAAA 1500*  
*AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 1550*  
*AAAAAAAAAA AAAAAA 1566*